Biotech & Investing Glossary — Key Terms Every Investor Should Know

The life science sector is dense with acronyms and regulatory shorthand. Understanding the language of drug development separates informed investors from speculators. This glossary distills 28 essential terms—from preclinical designations to commercial milestones—with concise definitions and real‑world context drawn from approved biologics, small molecules, and cutting‑edge modalities like mRNA and antibody‑drug conjugates.

FDA (U.S. Food and Drug Administration)

The federal agency responsible for evaluating the safety, efficacy, and quality of drugs, biologics, and medical devices before they can be marketed in the United States. The FDA’s Center for Drug Evaluation and Research (CDER) reviews most small‑molecule drugs, while the Center for Biologics Evaluation and Research (CBER) oversees vaccines and gene therapies. An approval from the FDA is the gold standard for global market entry.

Example: The FDA’s 2023 full approval of Leqembi (lecanemab) for Alzheimer’s disease marked the first anti‑amyloid antibody to convert from accelerated to traditional approval.

EMA (European Medicines Agency)

The EU’s centralized regulatory body, analogous to the FDA. The EMA grants marketing authorization valid across all EU member states plus Iceland, Liechtenstein, and Norway. While its standards are similarly rigorous, the EMA often reviews new chemical entities a few months later than the FDA, creating a predictable two‑step launch cadence.

Example: BioNTech and Pfizer’s COVID‑19 vaccine received EMA conditional marketing authorization in December 2020, three weeks after FDA emergency use authorization.

Phase I

The initial clinical trial stage, typically enrolling 20–80 healthy volunteers (or patients in oncology). Primary objectives are safety, tolerability, and pharmacokinetics, not efficacy. Dose‑escalation designs identify the maximum tolerated dose. Positive Phase I safety data allow progression to larger, efficacy‑focused studies.

Example: Moderna’s mRNA‑1273 COVID‑19 vaccine candidate cleared Phase I in mid‑2020 after demonstrating robust antibody responses with a manageable safety profile.

Phase II

An exploratory study enrolling 100–300 patients with the target condition. Phase II trials provide preliminary evidence of efficacy (through biomarker or clinical endpoints) and refine the dosing regimen. Success in Phase II triggers a go/no‑go decision for pivotal Phase III studies.

Example: Karuna Therapeutics’ Phase II EMERGENT‑1 trial of KarXT in schizophrenia met its primary endpoint, supporting progression to Phase III and eventual FDA approval.

Phase III

Large‑scale, often multicenter, randomized trials designed to demonstrate statistically significant efficacy and generate a comprehensive safety database. Phase III trials typically enroll hundreds to thousands of patients and form the core of a New Drug Application (NDA) or Biologics License Application (BLA).

Example: Novo Nordisk’s STEP program for semaglutide in obesity included four Phase III trials with over 4,500 participants, paving the way for Wegovy’s approval.

IND (Investigational New Drug Application)

A submission to the FDA that allows a sponsor to ship an unapproved drug across state lines for clinical trials. An IND includes preclinical data, manufacturing information, and a proposed clinical protocol. The FDA has 30 days to review the IND before clinical studies may begin.

Example: Editas Medicine’s IND for EDIT‑101, a CRISPR‑based therapy for Leber congenital amaurosis, was cleared by the FDA in 2018, enabling first‑in‑human dosing.

NDA (New Drug Application)

The formal request to the FDA for permission to market a new small‑molecule drug. The NDA includes all preclinical, clinical, and manufacturing data. A standard review takes 10 months from filing; priority review shortens this to 6 months for drugs addressing an unmet medical need.

Example: AbbVie’s NDA for Rinvoq (upadacitinib) in rheumatoid arthritis was approved in 2019 after priority review.

BLA (Biologics License Application)

The equivalent of an NDA for biologic products, including monoclonal antibodies, vaccines, gene therapies, and blood‑derived products. BLAs are reviewed by CBER or CDER depending on the product type. Biosimilars use an abbreviated pathway (351(k) BLA).

Example: Regeneron’s BLA for Eylea (aflibercept) was approved in 2011 based on two Phase III trials in wet AMD.

mRNA (Messenger RNA)

A platform technology that delivers synthetic messenger RNA encoding a target protein, which the patient’s cells then translate to elicit an immune response or produce therapeutic proteins. The success of mRNA‑based COVID‑19 vaccines has catalyzed a wave of programs in oncology, rare disease, and infectious diseases.

Example: Moderna’s mRNA‑4157 (V940), an individualized neoantigen therapy combined with Keytruda, showed a durable reduction in recurrence risk in melanoma, now in Phase III.

ADC (Antibody‑Drug Conjugate)

A targeted cancer therapy that links a highly potent cytotoxic payload to a monoclonal antibody via a chemical linker. The antibody binds to a tumor‑associated antigen, delivering the toxic agent directly to cancer cells while sparing healthy tissue. The linker stability and drug‑to‑antibody ratio are critical design parameters.

Example: Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) achieved unprecedented response rates in HER2‑low breast cancer, expanding the treatable population dramatically.

Orphan Drug Designation

A status granted by the FDA to drugs or biologics intended to treat rare diseases (affecting fewer than 200,000 people in the U.S.). Incentives include seven years of market exclusivity upon approval, tax credits for clinical trial costs, and exemption from user fees.

Example: Vertex Pharmaceuticals’ Trikafta (elexacaftor/tezacaftor/ivacaftor) had orphan designation for cystic fibrosis, helping the company command premium pricing.

Breakthrough Therapy Designation

An FDA expedited program for drugs that show substantial improvement over existing therapies on a clinically significant endpoint in early trials. Benefits include intensive FDA guidance and eligibility for rolling NDA/BLA submission.

Example: BeiGene’s Brukinsa (zanubrutinib) for mantle cell lymphoma received Breakthrough Therapy designation in 2019 before its accelerated approval.

Accelerated Approval

A pathway that allows earlier approval of drugs for serious conditions based on a surrogate endpoint reasonably likely to predict clinical benefit. Post‑approval confirmatory trials are required to verify the benefit; failure to do so can lead to withdrawal.

Example: Sarepta Therapeutics’ Exondys 51 (eteplirsen) for Duchenne muscular dystrophy was approved under this pathway in 2016 based on dystrophin expression, with ongoing confirmatory trials.

Clinical Endpoint

A measurable variable that reflects how a patient feels, functions, or survives. Endpoints are classified as primary (the main outcome used to determine trial success) or secondary (supportive measures). Hard endpoints like overall survival carry the most weight in regulatory decisions.

Example: In the KEYNOTE‑775 trial, the primary endpoints were progression‑free survival and overall survival for pembrolizumab plus lenvatinib in advanced endometrial cancer.

Placebo‑Controlled

A trial design in which a group of participants receives an inactive substance indistinguishable from the active treatment. The placebo arm controls for the placebo effect and natural disease fluctuation, allowing isolation of the drug’s true pharmacological effect.

Example: Biogen’s Phase III EMERGE trial of aducanumab included a placebo arm, though its post‑hoc analysis and subsequent approval remain controversial.

Double‑Blind, Randomized Trial

The gold standard for minimizing bias: neither participants nor investigators know who is receiving the experimental drug versus control. Treatment assignment is random, ensuring that confounding factors are evenly distributed.

Example: The pivotal SELECT trial for semaglutide (Wegovy) in cardiovascular outcomes enrolled 17,604 patients in a double‑blind, placebo‑controlled design, demonstrating a 20% reduction in major adverse cardiovascular events.

Bioavailability

The fraction of an administered drug dose that reaches systemic circulation unchanged. Intravenous drugs have 100% bioavailability; oral formulations often require absorption and first‑pass metabolism considerations. Bioavailability studies are critical for bridging formulations (e.g., tablet to injection).

Example: The oral tyrosine kinase inhibitor imatinib (Gleevec) exhibits high bioavailability (~98%), contributing to its once‑daily dosing convenience.

Biosimilar

A biological product highly similar to an already approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. Biosimilars are approved via an abbreviated regulatory pathway (351(k)) and create price competition upon patent expiry.

Example: Amgen’s Amjevita (adalimumab‑atto) was the first biosimilar to AbbVie’s Humira, launched in 2023 after a lengthy patent dispute settlement.

Biologic

A therapeutic product derived from living organisms or containing components of living organisms, including monoclonal antibodies, vaccines, cell‑based gene therapies, and recombinant proteins. Biologics are generally more complex and expensive to manufacture than small molecules.

Example: Roche’s Herceptin (trastuzumab) is a monoclonal antibody biologic that revolutionized HER2‑positive breast cancer treatment.

Small Molecule

A chemically synthesized drug with a low molecular weight, typically able to cross cell membranes and bind intracellular targets. Most orally administered drugs are small molecules. They are generally cheaper to manufacture and can be genericized more easily than biologics.

Example: Pfizer’s Lipitor (atorvastatin) is a small‑molecule statin that dominated the cholesterol market before patent expiry.

Pharmacokinetics (PK)

The study of how an organism affects a drug, described by absorption, distribution, metabolism, and excretion. PK parameters such as half‑life, Cmax, and AUC inform dosing intervals and potential drug‑drug interactions. Phase I trials primarily focus on PK characterization.

Example: The long half‑life of risankizumab (Skyrizi) allows quarterly dosing in psoriasis, improving patient convenience.

Pharmacodynamics (PD)

The study of a drug’s biochemical and physiological effects on the body—essentially what the drug does to the organism, including receptor binding, downstream signaling, and therapeutic effect. PD biomarkers help link dose to clinical outcome.

Example: In CAR‑T cell therapies, PD is monitored via serum cytokine levels (e.g., IL‑6) to manage cytokine release syndrome.

Adverse Event (AE) and Serious Adverse Event (SAE)

An AE is any untoward medical occurrence in a clinical trial participant; an SAE results in death, life‑threatening illness, hospitalization, disability, or a congenital anomaly. SAEs must be reported to regulators within 15 days. The overall safety profile is compiled in the integrated safety summary of an NDA/BLA.

Example: A GLP‑1 receptor agonist trial may list nausea as a common AE, while a caspase‑dependent hepatotoxicity signal could be an SAE.

Informed Consent

An ethical and legal requirement ensuring that trial participants understand the study’s purpose, procedures, risks, and potential benefits before enrollment. The consent form must be approved by an Institutional Review Board (IRB) or Ethics Committee.

Example: All participants in the mRNA‑based HIV vaccine trials (e.g., IAVI G003) signed informed consent documents detailing the experimental nature of the germline‑targeting approach.

Good Clinical Practice (GCP)

An international ethical and scientific quality standard for designing, conducting, recording, and reporting clinical trials. GCP compliance ensures data integrity and protection of human subjects. Violations can lead to FDA warning letters or data rejection.

Example: In 2022, the FDA issued a warning to a sponsor for GCP deficiencies including inadequate source documentation in a Phase II oncology trial.

Contract Research Organization (CRO)

A company that provides outsourced clinical trial services to pharmaceutical and biotech sponsors, including site monitoring, data management, biostatistics, and regulatory submissions. Large CROs such as IQVIA, ICON, and Parexel enable even virtual biotechs to run global Phase III programs.

Example: Moderna relied on PPD (now part of Thermo Fisher) as its primary CRO during the COVID‑19 vaccine Phase III trial, managing over 30,000 participants across 99 sites.

Orphan Drug Act

U.S. legislation passed in 1983 to incentivize development of treatments for rare diseases. It grants tax credits, fee waivers, and seven years of market exclusivity upon approval. More than 1,100 orphan designations have been approved by the FDA.

Example: Alexion’s Soliris (eculizumab) was developed under the Orphan Drug Act and became a multi‑billion‑dollar product despite targeting only a few thousand patients globally with paroxysmal nocturnal hemoglobinuria.

Surrogate Endpoint

A laboratory measurement or physical sign used as a substitute for a clinically meaningful endpoint, such as tumor shrinkage instead of overall survival. Regulatory agencies may accept surrogate endpoints for accelerated approval when a drug treats a serious or life‑threatening disease.

Example: The FDA approved Pfizer’s Xalkori (crizotinib) based on objective response rate (a surrogate endpoint) in ALK‑positive non‑small cell lung cancer, with confirmatory overall survival data required later.

Shelf Registration (Form S‑3)

A simplified SEC registration that allows public companies to issue securities (stock, warrants, debt) quickly after an initial registration “on the shelf.” Biotechs frequently use at‑the‑market (ATM) programs under an S‑3 to raise capital opportunistically without a full secondary offering.

Example: In 2024, Viking Therapeutics filed a $500 million mixed shelf to fund Phase III obesity trials of VK2735.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.